Intergroupe Francophone De Cancerologie Thoracique
Clinical trials sponsored by Intergroupe Francophone De Cancerologie Thoracique, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for mesothelioma: drug targets cancer from two angles Results expected Sep 2026 (estimated)
- Could a Chemo-Immunotherapy combo beat standard care for tough lung cancer? Results expected Nov 2026 (estimated)
-
Blood test may tailor lung cancer immunotherapy, sparing unnecessary treatment
Disease control Not yet recruitingThis trial is testing whether a blood test that detects cancer DNA can guide the use of durvalumab, an immunotherapy, after standard chemoradiotherapy in patients with stage III lung cancer that cannot be removed by surgery. The goal is to see if giving durvalumab only to patient…
Phase 2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for lung cancer patients with lung scarring: trial tests safer treatments
Disease control Not yet recruitingThis study is for people with advanced non-small cell lung cancer who also have interstitial lung disease (ILD), a condition that causes lung scarring. Many doctors avoid treating these patients due to risks of worsening ILD. The trial will test a specific chemotherapy as first t…
Phase 2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC